×

TESARO Appoints Jeffrey H. Hanke, Ph.D., as Executive Vice President, Research & Development, and Chief Scientific Officer

WALTHAM, Mass., June 29, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Jeffrey H. Hanke, Ph.D., to the newly created role of Executive Vice President, Research and Development, and Chief Scientific Officer. In this position, Dr. Hanke will report to Mary Lynne Hedley, Ph.D., President and COO of TESARO, and oversee TESARO's non-clinical research and development organizations, as well as the program management function. Dr. Hanke most recently served as Senior Vice President, Research, and Global Head of Biotherapeutics at Boehringer Ingelheim, Inc.

"Jeff is a great addition to the TESARO executive team," said Mary Lynne Hedley. "He brings to TESARO strong leadership skills, a successful track record in overseeing multiple oncology programs, and a wealth of experience in building R&D organizations. Jeff's deep expertise in immunology and oncology will be invaluable to TESARO as we continue to advance our portfolio of product candidates."

Dr. Hanke has more than twenty-five years of experience in biopharmaceutical research and development. He previously served as Vice President of Cancer Research at AstraZeneca, where he was responsible for building and leading the U.S. cancer research organization and establishing a robust portfolio of product candidates. He also served in several roles of increasing responsibility within the R&D organization at Pfizer, where he led teams in the areas of immunology, inflammation, allergy/respiratory, and oncology. Dr. Hanke received his Ph.D. in immunology and microbiology from Baylor College of Medicine and his M.S. in biology from Fordham University. He completed his post-doctoral training at the University of Texas Southwestern Medical School.

About TESARO

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing, and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include statements regarding the advancement of our portfolio of product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the execution and completion of clinical trials, uncertainties surrounding the timing of availability of data from our clinical trials, ongoing discussions with and actions by regulatory authorities, patient accrual rates for clinical trials, and other matters that could affect the timing of availability of data from or initiation of our clinical trials, uncertainties regarding regulatory approvals, uncertainties regarding certain expenditures, and other matters that could affect the availability or commercial potential of our drug candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see TESARO's Annual Report on Form 10-K for the year ended December 31, 2014.

CONTACT: Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or jdavis@tesarobio.com

Source:TESARO, Inc.